PlainRecalls
FDA Drug Moderate Class II Terminated

GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each with 10 individually blistered doses), Rx only, Manufactured by: Patheon Pharmaceuticals Inc., Cincinnati, OH 45237; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054. Carton NDC#: 68084-295-21 (Individual Dose NDC: 68084-295-11)

Reported: October 27, 2021 Initiated: September 17, 2021 #D-0020-2022

Product Description

GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each with 10 individually blistered doses), Rx only, Manufactured by: Patheon Pharmaceuticals Inc., Cincinnati, OH 45237; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054. Carton NDC#: 68084-295-21 (Individual Dose NDC: 68084-295-11)

Reason for Recall

Failed Dissolution Specifications: results were above specification.

Details

Recalling Firm
American Health Packaging
Units Affected
2,266 cartons
Distribution
Nationwide within the USA
Location
Columbus, OH

Frequently Asked Questions

What product was recalled?
GlipiZIDE Extended-Release Tablets, 2.5 mg, 30 Tablets (3 blister cards each with 10 individually blistered doses), Rx only, Manufactured by: Patheon Pharmaceuticals Inc., Cincinnati, OH 45237; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054. Carton NDC#: 68084-295-21 (Individual Dose NDC: 68084-295-11). Recalled by American Health Packaging. Units affected: 2,266 cartons.
Why was this product recalled?
Failed Dissolution Specifications: results were above specification.
Which agency issued this recall?
This recall was issued by the FDA Drug on October 27, 2021. Severity: Moderate. Recall number: D-0020-2022.